You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic Triple Negative Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Aug 31, 2023

Immunotherapy-related CRP Kinetics in Early and Metastatic

Recruiting
  • TNBC - Triple-Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 13, 2023

    TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)

    Recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Wuhan, Hubei, China
      Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
    Nov 5, 2023

    Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

    Not yet recruiting
    • Breast Neoplasms
    • Hangzhou, Zhejiang, China
      ZhejiangCH
    Nov 17, 2023

    Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

    Not yet recruiting
    • Metastatic Triple-Negative Breast Carcinoma
    • 89Zr-atezolizumab PET/CT
    • (no location specified)
    Feb 22, 2023

    Metastatic Triple-negative Breast Cancer Trial in Wuhan (Surufatinib, Tislelizumab)

    Not yet recruiting
    • Metastatic Triple-negative Breast Cancer
    • Wuhan, Hubei, China
      Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
    Feb 27, 2023

    Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer Trial in Changsha, Xiangyang (AK117,

    Recruiting
    • Metastatic Triple-negative Breast Cancer
    • Locally Advanced Triple-negative Breast Cancer
    • Changsha, China
    • +1 more
    Sep 8, 2022

    Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    May 2, 2023

    Triple Negative Breast Cancer Trial in Guangzhou (Chidamide combined with Zimberelimab)

    Recruiting
    • Triple Negative Breast Cancer
    • Chidamide combined with Zimberelimab
    • Guangzhou, Guangdong, China
      Sun Yat-sen University, Cancer Center
    Nov 20, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Duarte (drug, biological, other)

    Not yet recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • Metastatic Triple-Negative Breast Carcinoma
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Jan 6, 2023

    Triple Negative Breast Cancer Trial in Guangzhou (Capecitabine, Tucidinostat)

    Recruiting
    • Triple Negative Breast Cancer
    • Guangzhou, Guangdong, China
      Sun-yat sen university cancer center
    Nov 1, 2022

    Metastatic NSCLC, Metastatic Triple-negative Breast Cancer Trial in Houston (biological, drug, radiation)

    Active, not recruiting
    Has Results
    • Metastatic Non-small Cell Lung Cancer
    • Metastatic Triple-negative Breast Cancer
    • ADV/HSV-tk
    • +3 more
    • Houston, Texas
      Houston Methodist Cancer Center
    Dec 28, 2022

    Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

    Recruiting
    • Triple Negative Breast Cancer
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Sep 15, 2022

    Triple Negative Breast Cancer, Metastatic Breast Cancer Trial in Boston (Pembrolizumab, PVX-410)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • Metastatic Breast Cancer
    • Boston, Massachusetts
    • +2 more
    Dec 21, 2022

    Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

    Not yet recruiting
    • Triple Negative Breast Cancer
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jul 25, 2023

    Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

    Not yet recruiting
    • Triple-Negative Breast Cancer
    • Trastuzumab Deruxtecan
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jul 12, 2023

    Metastatic Triple-Negative Breast Carcinoma, Breast Cancer Trial in Dallas (Neratinib Oral Tablet, Ruxolitinib Oral Tablet)

    Not yet recruiting
    • Metastatic Triple-Negative Breast Carcinoma
    • Breast Cancer
    • Neratinib Oral Tablet
    • Ruxolitinib Oral Tablet
    • Dallas, Texas
      Baylor University Medical Center, Baylor Charles A Sammons Cance
    Aug 22, 2023

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

    Not yet recruiting
    • Anatomic Stage III Breast Cancer AJCC v8
    • +3 more
    • Biopsy
    • +4 more
    • (no location specified)
    Jan 4, 2023

    Metastatic Triple Negative Breast Cancer Trial in New Haven (Tumor infiltrating lymphocytes (TIL) LN-145)

    Recruiting
    • Metastatic Triple Negative Breast Cancer
    • Tumor infiltrating lymphocytes (TIL) LN-145
    • New Haven, Connecticut
      Yale School of Medicine
    Jul 20, 2022

    Triple Negative Breast Cancer (TNBC) Trial in China (B013+Nab-Paclitaxel)

    Recruiting
    • Triple Negative Breast Cancer (TNBC)
    • Guangzhou, Guangdong, China
    • +6 more
    Jan 29, 2023

    Eribulin-Based Regimen Versus Other Chemotherpy in

    Active, not recruiting
    • Breast Cancer
    • Eribulin-Based Regimen
    • +2 more
    • Fuzhou, Fujian, China
      Fujian Cancer Hospital
    Jul 18, 2023

    Triple Negative Breast Cancer Trial in Dallas (Drug 1: LY3023414; Drug 2: Prexasertib)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • Drug 1: LY3023414; Drug 2: Prexasertib
    • Dallas, Texas
      Baylor University Medical Center
    Jul 18, 2022

    Triple Negative Breast Cancer Trial in United States (Pembrolizumab, Cyclophosphamide)

    Active, not recruiting
    Has Results
    • Triple Negative Breast Cancer
    • Washington, District of Columbia
    • +4 more
    Nov 8, 2022

    Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

    Not yet recruiting
    • Triple-Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 27, 2023

    Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

    Terminated
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +2 more
    • Bintrafusp Alfa
    • Eribulin Mesylate
    • Houston, Texas
    • +1 more
    Oct 27, 2022